

June 17, 2014 in Paris

The SIMV organizes the first R&D dating for Animal Health and Innovation on 2 and 3 December 2014 in Lille (Grand Palais)

Les Rencontres de recherche en santé animale

The French association of animal health industry (SIMV) organizes the first R&D dating for animal health and innovation on December 2nd and 3rd 2014 in Lille, hosted within BioFIT. These meetings aim to initiate high-level exchanges between teams from private and public research and biotechnology companies, in veterinary and human medicine in France and Europe. These meetings are organized in partnership with the Animal Health Carnot Institute, Eurasanté, Medicen Paris Region, the French Alliance for Research and Innovation in health industries and the Companies for Accelerating the Technology Transfer¹. Many other organizations provide support².

The French association of animal health industry (SIMV) is pleased to announce **the first “R&D dating for animal health and innovation”**. The objective of these meetings is to initiate high-level exchanges between research departments of the health industry (veterinary and human), and public research, as well as biotechnology companies (start-ups) to promote French expertise in animal health, leading to partnerships (public-private and private-private) and to promote innovation. Today, public-private and private-private partnerships are essential to foster innovation. This event will lead to business to business meetings (BtoB).

“By organizing these meetings, the SIMV intends to promote more innovative and better value animal health research, by strengthening the leading position of France in Europe. In addition, these conditions will enable to meet the challenges of high impact diseases in both animal - and public health, at the human-animal interface ”says Jean-Louis Hunault, President of SIMV.

Beyond the federation of research actors in animal health, the SIMV intends with the organization of these meetings to amplify exchanges between animal - and human health in order to mutually accelerate the development of new molecules, thereby promoting the “One Health” concept.

All actors involved in animal health innovation or with animal health applications are invited to attend these meetings, which are organized in the form of a business convention to benefit from the French and European expertise in this sector.

¹ SATT Idfinnov, SATT Nord, SATT Conectus Alsace

² The clusters Atlanpôle biothérapie and Eurobiomed, CVT Valorisation Sud, IRT Bioaster, DVS "Innovation en Vaccinologie" du CVT Aviesan, Der Bundesverband für Tiergesundheit e.V.(German association of animal health industry), SATT Sud-Est, SATT Toulouse Tech Transfer

France is the European leader in research and manufacture of veterinary medicines and reagents with 50 production sites in France and many research centers. The global attractiveness of France in matters of animal health lies in the density of this industrial, veterinary, and professional fabric, in its recognized scientific and technical expertise, and in the capacity of its manufacturers to invest in managing networked R&D projects and international projects. The veterinary medicines industry invests 10 to 12% of its share of turnover to R&D.

In order to broaden the possibilities of encounters and particularly exchanges between "animal - and human health", the SIMV chose to host its event within the event BioFIT on December 2nd and 3rd, 2014 in Lille, at the same place and during the same period thereby benefitting from its European set-up.

The BioFIT's 3rd edition is the only international partnering event in Europe dedicated to technology transfer and collaborative research in the Life Sciences sector, gathering the right mix of attendees to boost up licensing deals and research collaborations.

The Animal Health Carnot Institute, Eurasanté, Medicen Paris Region, the French alliance for research and innovation in health industries and the Companies for Accelerating the Technology Transfer¹ are partnering this event with the SIMV. In addition, many other organizations expressed their support to this event².

Let's Commit ourselves to animal - and public health innovation together!

About the organizer - SIMV: www.simv.org

The **SIMV** represents manufacturers and marketers (on the French market) of medicines and reagents for pets and for farm animals. It is the DNA that runs through our entire industry, at the core of many of our interactions.

France is the European leader in research and manufacture of veterinary medicines and reagents, with over 6,600 employees, and the largest therapeutic arsenal in Europe (2,700 marketing authorisations), 50 production sites and many research centers. The global attractiveness of France in matters of animal health lies in the density of this industrial, veterinary, and professional fabric, in its recognized scientific and technical expertise, and in the capacity of its manufacturers to invest in managing networked R&D projects and international projects.

To contribute to the competitiveness of its member companies, the SIMV federates laboratories around joint projects, proposes collective strategies in response to the expectations of society and represents the views of its members in its decision-making environment.

With the ambition to contribute to highlight the innovations of tomorrow, the SIMV is a member of networks such as the French Network for Animal Health (RFSA), mirror group of the European Platform (ETPGAH), Hippolia (French foundation dedicated to equine research), ICSA (Animal Health Carnot Institute) as well as ARIIS (French Alliance for Research and Innovation of Health Industries).

About the partners:

Animal Health Carnot Institute (ICSA)

ICSA, the French research network dedicated to the health of livestock, was labeled "Carnot Institute" by the French Ministry of higher education and research in May 2011. This label is awarded to academic research networks that collaborate efficiently with socio-economic stakeholders.

The mission of ICSA is to support innovation, technology transfer and public-private partnership in the fields of infectious diseases, nutrition and genetics of livestock. For this, the network provides its industrial partners:

- A single point of contact dedicated to companies with access to the wide range of skills to conduct collaborative research
- A simplified contracting process to ensure listening, traceability, reliability and speed in the processing of contracts.

Key figures of ICSA: 923 research personnel (full-time equivalent) including 130 PhD students, 14 units / laboratories, 38 patent families, 72 active licenses. Per year, about 30 European projects and 80 projects ANR ongoing, 700 publications, 8 200 k€ partnership research incomes, 130 contracts with the private sector, 80 industry partners.

Eurasanté:

Alongside the Nutrition Health Longevity Cluster, Eurasanté is the economic development agency focusing on biotech, nutrition and healthcare activities in Northern France. Eurasanté has four principal missions:

- Promote Lille Northern France Bio Cluster to French and foreign industries and research centers. On this specific point, Eurasanté's work consists in supporting research by identifying and accelerating R&D partnerships or by helping scientists to set-up their business, especially through its Bio Incubator.
- Promote and develop the Eurasanté Bio Business Park, located on the largest university-campus hospital in Europe.
- Go along with regional companies in their business development or scientists willing to add economic value to their work, thanks to a complete range of services and know-how.
- Support French and foreign companies to set-up a business in Lille and Northern France.

In 2013, the field of health and life sciences counts around 22,000 employees and 800 companies working in the fields of Biology, Health and Nutrition, in particular on major themes such as diabetes, age-related diseases, Inflammatory Bowel Diseases (IBD), resistance to treatment and tumor dormancy.

Medicen Paris Region: www.medicen.org

One of Europe's largest cluster in Life Sciences and Healthcare and your best gateway to access European biotechnologies markets.

Our mission is to highlight and reinforce the Paris Region as Europe's leading industrial center for medical devices innovations and health technologies. With over 200 members, our goal is to increase the attractiveness of the Paris region, to strengthen the international competitiveness of the health sector and to develop the economic growth of our members in strategic markets through collaborative innovation. Since the cluster was created in 2005, 226 R&D projects have been accredited and funded by the French State and local authorities, for a total project budget of €846 million and €390 million of public subsidies.

Alliance for Research and Innovation in Health Industries (Ariis): www.ariis.fr

Created in 2010, ARIIS aims at decompartmentalizing private research and fostering synergies between pharma, medical technology, diagnosis tools, biotechnologies for human and veterinary use, and developing the best environment to enhance innovation. Unique in the world, ARIIS is a key asset for France competitiveness and attractiveness to foster the development of innovative products, i.e. from the idea to making it available to patients, bringing together all the actors of the health industry. Besides, human and animal health being linked by the “One health” concept, a global approach of health is necessary.

With the backing of the French Federation of Health Industries (FEFIS) which federates the twelve French health industry associations, ARIIS counts about fifty member companies.

As Aviesan’s privileged contact, ARIIS interacts with all stakeholders, training, informing and favoring dialogue and partnerships between scientists in research and innovation in order to:

- Build bridges between sectors with cultures that sometimes differ greatly
- Enhance visibility of research and development activities in France
- Identify obstacles to make the French territory attractive for research and development activities and propose solutions and targets for further improvements

Companies for Accelerating the Technology Transfer (SATT):

The Companies for Accelerating the Technology Transfer (Les Sociétés d’Accélération du Transfert de Technologies or SATT) are French semi-public institutes for the development and commercialization of public research and innovation products. They are part of the measures implemented by the French National Research Agency (ANR) for the “Investment for the Future” program (program with a public funding of 35 B€, and additional private investments), whose ambition is to meet the innovation gap.

The SATT were created to be the privileged interface between companies and public research: they bring their expertise and resources in the maturation process and the transfer of technologies, and are the bridge between the inventive stage of technology and the needs of industry.

Bringing professionalism, expertise and financing, the SATT come along the process of projects of the transfer chain according to the needs of the future receptor in the process of co-conception and co-maturation. By increasing the Technology Readiness Levels, they also participate in reducing the risk for companies. The SATT have become an actor of economic development to reinforce company competitiveness, with an emphasis on SME and start-ups.

They are a key part of the French innovation ecosystem by linking the State, the public research operators and the industry in regional structures. They participate in the development of growth and jobs through innovation by improving competitiveness among French companies and creating start-ups through innovation coming from public research.

SATT Partners: SATT idfinnov, SATT Nord, SATT Conectus Alsace

About BioFIT:

BioFIT, with an exclusive partnership with EBD Group, is the only international partnering event in Europe dedicated to technology transfer and collaborative research in Life Sciences sector, gathering the right mix of attendees to boost up licensing deals and research collaborations. With one third of TTOs and academia, one third of pharma, biotech, medtech and one third of VCs, service industries and clusters, BioFIT already

attracted top leaders from the industry as well as tech transfer and licensing professionals featuring [partnering](#), [conferences](#) and [technologies presentations](#).

The BioFIT's 3rd edition will be held on December 2nd & 3rd, 2014 in Lille (France) and will gather around 800 attendees from more than 60% international among which top global pharma companies and leaders in biotechnology and tech transfer.

You wish to participate? Contact us!

Contact:

Laetitia Steffen

Communication manager

Syndicat de l'industrie du médicament et réactif vétérinaires

Tel : +33 (0)1 53 34 43 49 / l.steffen@simv.org

